Encompass Health Co. (NYSE:EHC) Shares Bought by Phocas Financial Corp.

Phocas Financial Corp. increased its position in Encompass Health Co. (NYSE:EHC - Free Report) by 112.4% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 99,875 shares of the company's stock after buying an additional 52,847 shares during the period. Phocas Financial Corp. owned about 0.10% of Encompass Health worth $6,664,000 at the end of the most recent quarter.

Several other hedge funds also recently bought and sold shares of the company. Lazard Asset Management LLC boosted its holdings in Encompass Health by 14.3% in the 4th quarter. Lazard Asset Management LLC now owns 1,290 shares of the company's stock worth $77,000 after buying an additional 161 shares during the period. Bank of Montreal Can lifted its stake in Encompass Health by 1.5% in the 1st quarter. Bank of Montreal Can now owns 11,340 shares of the company's stock worth $806,000 after purchasing an additional 173 shares in the last quarter. Creative Planning lifted its stake in Encompass Health by 3.5% in the 2nd quarter. Creative Planning now owns 6,074 shares of the company's stock worth $340,000 after purchasing an additional 204 shares in the last quarter. First Horizon Advisors Inc. lifted its stake in Encompass Health by 18.8% in the 1st quarter. First Horizon Advisors Inc. now owns 1,415 shares of the company's stock worth $77,000 after purchasing an additional 224 shares in the last quarter. Finally, Treasurer of the State of North Carolina lifted its stake in Encompass Health by 0.5% in the 3rd quarter. Treasurer of the State of North Carolina now owns 48,339 shares of the company's stock worth $3,246,000 after purchasing an additional 231 shares in the last quarter. Institutional investors own 97.25% of the company's stock.

Encompass Health Trading Down 1.4 %

Encompass Health stock traded down $1.17 during midday trading on Friday, reaching $80.49. The stock had a trading volume of 611,053 shares, compared to its average volume of 746,610. The company has a quick ratio of 1.28, a current ratio of 1.28 and a debt-to-equity ratio of 1.19. Encompass Health Co. has a 52-week low of $57.55 and a 52-week high of $83.73. The firm has a market cap of $8.06 billion, a price-to-earnings ratio of 23.20, a price-to-earnings-growth ratio of 1.49 and a beta of 0.94. The company has a fifty day moving average of $76.68 and a 200 day moving average of $69.91.

Encompass Health (NYSE:EHC - Get Free Report) last posted its quarterly earnings data on Wednesday, February 7th. The company reported $0.95 earnings per share for the quarter, topping analysts' consensus estimates of $0.83 by $0.12. Encompass Health had a net margin of 7.33% and a return on equity of 17.69%. The company had revenue of $1.25 billion for the quarter, compared to analyst estimates of $1.24 billion. On average, analysts anticipate that Encompass Health Co. will post 3.96 earnings per share for the current fiscal year.

Encompass Health Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Monday, April 15th. Shareholders of record on Monday, April 1st will be paid a $0.15 dividend. The ex-dividend date of this dividend is Thursday, March 28th. This represents a $0.60 dividend on an annualized basis and a yield of 0.75%. Encompass Health's dividend payout ratio is currently 17.29%.

Analysts Set New Price Targets

Several analysts have commented on the stock. Stephens reiterated an "overweight" rating and issued a $85.00 price target on shares of Encompass Health in a research note on Tuesday, January 16th. Truist Financial boosted their price target on shares of Encompass Health from $82.00 to $86.00 and gave the stock a "buy" rating in a research note on Friday, February 9th. William Blair restated an "outperform" rating on shares of Encompass Health in a research report on Wednesday, February 7th. Royal Bank of Canada restated an "outperform" rating and set a $83.00 target price on shares of Encompass Health in a research report on Friday, February 9th. Finally, Mizuho upped their target price on shares of Encompass Health from $77.00 to $82.00 and gave the company a "buy" rating in a research report on Friday, February 9th. Eight research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat, the company currently has an average rating of "Buy" and a consensus price target of $83.22.

Encompass Health Company Profile

Encompass Health Corporation provides post-acute healthcare services in the United States and Puerto Rico. It owns and operates inpatient rehabilitation hospitals that provide medical, nursing, therapy, and ancillary services. The company provides specialized rehabilitative treatment on an inpatient basis to patients who have experienced physical or cognitive disabilities or injuries due to medical conditions, such as strokes, hip fractures, and various debilitating neurological conditions.